GlassScriptPhysician profile
Nydia Sanchez
NPI 1598757007
$4,422.69
in general payments reported to CMS, 2019-2025
25 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $115 · 2021: $281 · 2022: $614 · 2023: $891 · 2024: $1,114 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,066.29 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $552.62 | 2019-2025 | |
| Celgene Corporation | $290.35 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $258.67 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $222.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $182.35 | 2019-2025 | Gattex, Entyvio |
| Genzyme Corporation | $176.47 | 2024-2025 | |
| Pfizer INC. | $98.76 | 2023-2025 | |
| Janssen Biotech, INC. | $81.73 | 2021-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $78.87 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.09 | 2021-2024 | Xifaxan |
| Qol Medical, LLC | $63.81 | 2024 | Sucraid |
| Ardelyx, INC. | $38.81 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $33.74 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $33.59 | 2024 | Vegzelma |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.78 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $25.59 | 2019-2021 | |
| Amgen INC. | $23.72 | 2023 | Amjevita, Avsola |
| Daiichi Sankyo INC. | $21.41 | 2023 | Injectafer |
| Evoke Pharma, INC. | $16.57 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.14 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.59 | 2021 | |
| Novo Nordisk INC | $14.53 | 2025 | Wegovy |
| Shionogi INC | $13.30 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nydia Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.